# Shingrix In Recipients of Allogeneic Transplants

> **NCT05775718** · PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 55 (estimated)

## Conditions studied

- Bone Marrow Transplant
- Stem Cell Transplant

## Interventions

- **DRUG:** Zoster Vaccine Recombinant

## Key facts

- **NCT ID:** NCT05775718
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2028-01-20
- **Final completion:** 2030-12-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775718, "Shingrix In Recipients of Allogeneic Transplants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05775718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*